Covidien

Bioventus Names Robert Claypoole as President and Chief Executive Officer

Retrieved on: 
Tuesday, December 19, 2023
Covidien, History, Johnson & Johnson, Medtronic, Growth, Patient, Management

DURHAM, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert (Rob) Claypoole as Bioventus’ President and Chief Executive Officer and a member of its Board of Directors, effective January 10, 2024.

Key Points: 
  • DURHAM, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert (Rob) Claypoole as Bioventus’ President and Chief Executive Officer and a member of its Board of Directors, effective January 10, 2024.
  • Mr. Claypoole succeeds Mr. Anthony Bihl who has served as interim CEO and a director on the Board since April 2023.
  • He most recently served as Executive Vice President at Mölnlycke Health Care AB, where he led Mölnlycke’s $1.2 billion global Wound Care business.
  • “We are excited to have Rob join Bioventus and build upon the significant improvements made this year to further elevate our execution and overall performance,” said William A. Hawkins, Bioventus’ executive chairman.

BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors

Retrieved on: 
Wednesday, December 13, 2023
AdvaMed, Portable ultrasound, Wound healing, Regenerative medicine, Smith, Amputation, Face, Wound, Growth, OTC, Covidien, MITA, Management

(OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces the appointment of Mr. Thomas J. Dugan to the position of Chairman of the Board.

Key Points: 
  • (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces the appointment of Mr. Thomas J. Dugan to the position of Chairman of the Board.
  • Mr. Dugan brings a wealth of experience to BioStem, with proven, hands-on expertise as a senior executive who has transformed businesses, established new market opportunities, and driven growth in the face of strong competition.
  • BioStem Technologies CEO, Jason Matuszewski, said, “I am delighted to welcome Mr. Dugan to BioStem’s Board of Directors.
  • Mr. Dugan served on the board of directors of Rita Medical Systems (NASDAQ: RITA), which was acquired by AngioDynamics, and various venture-backed medical device companies.

Morphic Medical Welcomes New Additions to Board of Directors

Retrieved on: 
Monday, November 13, 2023
General Health, Diabetes, Medical Devices, Health, Clinical Trials, Obesity, Bausch, Acquisition, Transport, Surgery, Senior, Medtronic, Risk, DSM-IV codes, Patient, Strategic planning, Medicine, Conformal, Marketing, University, GI, Instrument, Glycated hemoglobin, Operating partner, INSEAD, LivaNova, Pharmaceutical industry, Boston Scientific, Covidien

Morphic Medical , creator of the world’s first medical device designed to target the underlying cause of type 2 diabetes, today announced the addition of James Reinstein, Teresa Matterelli, and John Barr to the company’s Board of Directors.

Key Points: 
  • Morphic Medical , creator of the world’s first medical device designed to target the underlying cause of type 2 diabetes, today announced the addition of James Reinstein, Teresa Matterelli, and John Barr to the company’s Board of Directors.
  • Before joining Conformal, Mr. Reinstein served as President, CEO, and board member for several other medical device and diagnostic companies including Saranas Inc., Cutera Inc., Drawbridge Health Inc., and Aptus Endosystems.
  • “I look forward to working with Morphic Medical and making a difference in the lives of patients suffering from metabolic diseases such as diabetes and obesity,” said Ms. Mattarelli.
  • Prior, Mr. Barr served on the Board of Directors of Valeritas Holdings Inc., a medical technology company focused on the treatment of diabetes.

LifeLens Technologies Expands Executive Leadership Team and Board of Directors

Retrieved on: 
Wednesday, November 8, 2023
NYSE, Stryker, Covidien, Acquisition, Boston Scientific, Glass, INSP, TCMD, Johnson & Johnson, Patient, Obstructive sleep apnea, Regis Corporation, Management

PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors:

Key Points: 
  • PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors:
    Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive Officer
    “With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens team,” said Dan Sullivan, Chief Executive Officer and Chairman of the Board of Directors of LifeLens.
  • Mr. Sullivan brings over 40 years of leadership in the medical device industry where he has been a principal, chief executive officer, board member or co-founder of 11 separate start-up companies, 10 of which have been acquired.
  • Richard Buchholz was appointed to the LifeLens’ Board of Directors, effective October 2023.
  • Mr. Buchholz also served as the Chief Financial Officer of Vascular Solutions, Inc., which was acquired by Teleflex Incorporated in 2017.

LivaNova Board Appoints J. Christopher Barry as New Director

Retrieved on: 
Friday, October 6, 2023
Medical Devices, Surgery, Hospitals, Clinical Trials, Health Technology, Cardiology, Other Health, Biotechnology, General Health, Health, Surgical Innovation, Medtronic, Senior, Retirement, Texas Tech University, Audit, LivaNova, Interim, LIVN, Growth, Marketing, PLC, Environmental science, NuVasive, Covidien, Patient, Pension fund, Management

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.
  • Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December 31, 2023.
  • “The LivaNova Board of Directors is pleased to welcome Chris Barry,” said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova.
  • With these changes, the LivaNova Board will be comprised of 10 Directors until Saia’s retirement at the end of the year.

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests

Retrieved on: 
Thursday, September 7, 2023
Oncology, Medical Supplies, Health, Hospitals, Genetics, Biotechnology, Baxter, 2005 in television, MBA, Multimedia, École centrale de Lyon, Baxter International, Guerbet, Hospital, Patient, Physician, Laboratory, Engineering, Siemens Healthineers, IVD, Small Business Saturday, Covidien, Pharmaceutical industry, Medical device

Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France.
  • She will lead the global expansion of Veracyte’s tests and will also serve as site lead for the company’s Marseille operations.
  • View the full release here: https://www.businesswire.com/news/home/20230907364591/en/
    Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit.
  • Taine’s extensive international management experience and commercial leadership make her the ideal person to lead the global expansion of Veracyte’s IVD test menu.

SHINE Technologies Names Harrie Buurlage Chief Commercial Officer of Isotopes

Retrieved on: 
Monday, September 11, 2023
Curium, Pupa, NRG, Mallinckrodt, Nuclear Regulatory Commission, Business development, Radiation, Covidien, University, Cancer, Radiopharmaceutical, Ytterbium, Certification, Nuclear medicine, Patient, Shine Technologies, Physics, University of Groningen, Growth, Diagnosis, SHINE, Medical imaging, Isotope

JANESVILLE, Wis., Sept. 11, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced that Harrie Buurlage has been named Chief Commercial Officer of Isotopes. Buurlage, who has been the General Manager of SHINE Europe since 2019, will now oversee all commercial aspects of SHINE's therapeutic and diagnostic medical isotope divisions. Supporting Buurlage in driving the growth of SHINE's medical isotope business will be Magdalena Brzezowska, a proven leader with extensive commercial experience in radiopharmaceuticals, who has been named Vice President of Sales and Business Development.

Key Points: 
  • JANESVILLE, Wis., Sept. 11, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced that Harrie Buurlage has been named Chief Commercial Officer of Isotopes.
  • Buurlage, who has been the General Manager of SHINE Europe since 2019, will now oversee all commercial aspects of SHINE's therapeutic and diagnostic medical isotope divisions.
  • He was the Chief Operating Officer at NRG in the Netherlands, overseeing key nuclear installations, and the global director for nuclear manufacturing at Covidien USA, now Curium Pharma.
  • "SHINE is well-positioned to provide increased access to life-saving medicine, and I look forward to helping usher in the next era of medical isotope production," Buurlage said.

Zimmer Biomet Announces Key Updates to Company's Executive Leadership Team

Retrieved on: 
Tuesday, September 5, 2023
Pennsylvania State University, Bachelor's degree, Medicine, Bachelor, UnitedHealth Group, Hip, University, Senior, Marketing, Erasmus University Rotterdam, Business economics, Business, MBA, Innovation, Thomas Jefferson University, Economics, Strategic leadership, Medtronic, University of Richmond, Acquisition, Novartis, Patient, Thomas Jefferson University Hospital, Region, Chief innovation officer, Michelin, Teleflex, Orthopedic surgery, NYSE, Zuilen, Covidien, Management, Virginia Tech, Adult, Optum

WARSAW, Ind., Sept. 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive Leadership Team. Wilfred van Zuilen has been promoted to Group President, EMEA; Mark Bezjak was promoted to President of the Americas; and Chief Science, Technology and Innovation Officer Nitin Goyal, M.D. has been appointed to the Executive Leadership Team, all reporting directly to President and Chief Executive Officer Ivan Tornos.

Key Points: 
  • Appointed to Executive Leadership Team
    WARSAW, Ind., Sept. 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive Leadership Team.
  • has been appointed to the Executive Leadership Team, all reporting directly to President and Chief Executive Officer Ivan Tornos.
  • "The expansion of Zimmer Biomet's Executive Leadership Team coincides with our renewed focus on commercial execution and innovation to drive the Company forward," said Mr. Tornos.
  • Wilfred Van Zuilen Promotion to Group President, EMEA
    Mr. van Zuilen joined Zimmer Biomet in June 2021 as President, EMEA.

RAMPART IC Announces the Addition of Rob Williamson to Its Board of Managers

Retrieved on: 
Saturday, September 2, 2023
Radiation, Intervention, International Atomic Energy Agency, E pluribus unum, SCAI, Catheter, IC, Multimedia, Foxhollow School, Interventions, Medtronic, Physician, LW, Pharmaceutical industry, Management, Medical imaging, Nursing, Covidien, Rampart, M1128

BIRMINGHAM, Ala., Sept. 2, 2023 /PRNewswire-PRWeb/ -- RAMPART IC has named Rob Williamson to its Board of Managers. Rob has spent the last 25 years in the medical devices industry, with companies such as Medtronic, Covidien, ev3, FoxHollow, and Bard. Most recently Rob served as the vice president of sales for Shockwave Medical where he built a sales team of more than 300 field reps and achieved more than $500M in revenue. Rob brings a wealth of start-up, commercial, and board experience to Rampart IC.

Key Points: 
  • BIRMINGHAM, Ala., Sept. 2, 2023 /PRNewswire-PRWeb/ -- RAMPART IC has named Rob Williamson to its Board of Managers.
  • "The Rampart team is excited and honored to have Rob join our Board of Managers and leadership team," said Rampart President and CEO Tom Livingston.
  • "The Rampart team is excited and honored to have Rob join our Board of Managers and leadership team," said Rampart President and CEO Tom Livingston.
  • "The Rampart team is excited and honored to have Rob join our Board of Managers and leadership team," said Rampart President and CEO Tom Livingston.

Bryan Hanson Named CEO of 3M's Health Care Business Group

Retrieved on: 
Tuesday, August 22, 2023
Minimally invasive procedure, Walgreens Boots Alliance, Massachusetts College of Liberal Arts, Medical device, Senior, Pharmacia, Surgery, Information technology, Zimmer Biomet, Culture, Schering-Plough, Women's Health Care Nurse Practitioner-Board Certified, Roman, Pharmacia & Upjohn, Bristol Myers Squibb, Sale, Cox, Cardinal Health, Patient, Health care, Texas Instruments, Outline of health sciences, Seattle Mariners, Growth, Medtech, NYSE, Management, Pharmaceutical industry, Nursing, AmeriCares, Medtronic, Novartis, Covidien

Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.

Key Points: 
  • Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.
  • 3M's Health Care Business Group, with $8.4 billion in sales in 2022, is a diversified health care technology leader with a deep and diverse portfolio of trusted brands, global capabilities, and leadership in attractive end market segments such as wound care, oral care, health care IT, and biopharma filtration.
  • As a standalone business, Health Care will be well-positioned to deliver industry-leading innovation that enables better, smarter, and safer health care for patients worldwide.
  • "I am honored and excited to join 3M's Health Care Business Group at such an important time in its evolution," said Hanson.